Overview

Trial Investigating the Absorption, Metabolism and Excretion After a Single Subcutaneous Dose of [3H]-Semaglutide in Healthy Male Subjects

Status:
Completed
Trial end date:
2014-04-28
Target enrollment:
Participant gender:
Summary
This trial is conducted in Europe. The aim of the trial is to investigate the absorption, metabolism and excretion after a single subcutaneous dose of [3H]-semaglutide in healthy male subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Novo Nordisk A/S